Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study

Fetal and early childhood environment, including the nutritional status of the pregnant mother and the infant, are considered critical for growth and risk of disease in later life.1 Many people in developing countries are not only malnourished but also chronically exposed to high levels of toxic fungal metabolites (mycotoxins). One family of mycotoxins, the aflatoxins, are carcinogenic and immunotoxic and cause growth retardation in animals.2 Aflatoxins contaminate staple foods in West Africa, particularly maize and groundnuts, as a result of hot, humid storage conditions that promote fungal growth. High exposure to aflatoxins occurs throughout childhood in the region, 3 4 suggesting that growth and development could be critically affected. We assessed exposure to aflatoxins in relation to anthropometric measures in children in Benin and Togo. We studied 480 children (aged 9 months to 5 years) from 16 villages in four geographic zones (four in each zone): Sudan savannah, north Guinea savannah, south Guinea savannah, and coastal savannah. The Ministries for Health in Benin and Togo gave ethical …

[1]  R. Luepker,et al.  Delayed Hospital Arrival for Acute Stroke: The Minnesota Stroke Survey , 1998, Annals of Internal Medicine.

[2]  Kelly R. Evenson,et al.  Prehospital and In-Hospital Delays in Acute Stroke Care , 2001, Neuroepidemiology.

[3]  A. Hall,et al.  Primary prevention of hepatocellular carcinoma in developing countries. , 2000, Mutation research.

[4]  H. Whittle,et al.  Hepatitis B infection and aflatoxin biomarker levels in Gambian children , 2000, Tropical medicine & international health : TM & IH.

[5]  E. Susser,et al.  Commentary: The impact of fetal and infant exposures along the life course. , 2001, International journal of epidemiology.

[6]  W. Hacke A late step in the right direction of stroke care , 2000, The Lancet.

[7]  A. Hall,et al.  11 – Epidemiology of Aflatoxin-Related Disease , 1993 .

[8]  W. Rosamond,et al.  Rapid response to stroke symptoms: the Delay in Accessing Stroke Healthcare (DASH) study. , 1998, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[9]  W. Rosamond,et al.  Time delays in accessing stroke care in the emergency department. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[10]  J. Grotta,et al.  Current emergency department management of stroke in Houston, Texas. , 1995, Stroke.

[11]  C. Castleden,et al.  Factors Delaying Hospital Admission After Stroke in Leicestershire , 1992, Stroke.

[12]  W. Rosamond,et al.  Determinants of Use of Emergency Medical Services in a Population With Stroke Symptoms: The Second Delay in Accessing Stroke Healthcare (DASH II) Study , 2000, Stroke.

[13]  P. Hainaut,et al.  Hepatocellular carcinoma: from gene to public health. , 1997, Journal of the National Cancer Institute.

[14]  Gary W. Mathison,et al.  The toxicology of aflatoxins: Human health, veterinary, and agricultural significance , 1997 .

[15]  R E Latchaw,et al.  Recommendations for the establishment of primary stroke centers , 2000 .

[16]  J. Kostis,et al.  Delay in Presentation and Evaluation for Acute Stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.) , 1997, Stroke.

[17]  J. Broderick,et al.  Acute stroke: delays to presentation and emergency department evaluation. , 1999, Annals of emergency medicine.

[18]  J. Grotta Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside. The Feinberg lecture. , 1999, Stroke.

[19]  PerWester,et al.  Factors Associated With Delayed Admission to Hospital and In-Hospital Delays> in Acute Stroke and TIA , 1999 .

[20]  D. Pandey,et al.  Critical factors determining access to acute stroke care , 1998, Neurology.

[21]  J. Noland,et al.  HOW IT WAS IN HOUSTON, TEXAS , 1969 .

[22]  D. Barer,et al.  Practicability of early treatment of acute stroke , 1992, The Lancet.

[23]  G. Hankey,et al.  Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.